Helocyte, founded by Fortress Biotech, Inc., is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel immunotherapies aimed at preventing and treating cancer and infectious diseases, particularly cytomegalovirus (CMV). The company's core mission is to harness the power of the immune system to combat these severe health challenges. Helocyte's product pipeline includes innovative therapies like CMV Triplex and ConVax, targeting both oncology and infectious disease markets.
Notable figures affiliated with Helocyte include its experienced management team and a distinguished scientific advisory board. The company has achieved significant milestones in advancing its clinical trials and securing strategic partnerships. Helocyte's impact lies in its potential to revolutionize treatment paradigms for cancer and CMV, offering hope for improved patient outcomes through cutting-edge immunotherapy solutions.
